News AHA: MSD's oral PCSK9 matches injectables MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill.
News Roche's oral MS hope fenebrutinib hits the mark in phase 3 Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.
News AHA: AZ's baxdrostat impresses in resistant hypertension AstraZeneca's data reveal for resistant hypertension treatment baxdrostat suggests its optimism about big sales for the drug could be justified.
News AHA: Cash for drug adherence study has disappointing result People with hypertension were twice as likely to take medicine regularly when offered cash rewards, but that didn't improve their blood pressure.
News MFN model for Medicaid revealed by CMS The Trump administration has released details of a most-favoured nation (MFN) drug pricing programme for medicines provided by Medicaid.
News Pfizer, Metsera $10bn marriage back on after rough patch Pfizer has won the battle for obesity drug developer Metsera, after rival Novo Nordisk said that it would not increase its bid above $10bn.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
